<DOC>
	<DOCNO>NCT02550535</DOCNO>
	<brief_summary>This Phase I/II trial determine safety , clinical efficacy feasibility gene-modified WT1 TCR therapy patient myelodysplastic syndrome ( MDS ) acute myeloid leukaemia ( AML ) . Patient 's white blood cell ( T cell ) modify transfer gene enables make new T cell receptor ( TCR ) recognize fragment protein call WT1 ( Wilms ' tumour 1 ) present abnormally high level surface myelodysplastic leukaemic cell . In trial , approximately 25 participant Human Leukocyte Antigen A2 ( HLA-A*0201 ) tissue type fail achieve maintain IWG define response follow hypomethylating agent therapy recruit .</brief_summary>
	<brief_title>A Phase I/II Study Gene-modified WT1 TCR Therapy MDS &amp; AML Patients</brief_title>
	<detailed_description>This Phase I/II trial determine safety , clinical efficacy feasibility gene-modified WT1 TCR therapy . Following provision inform consent , subject undergo screening assessment , include HLA-A*0201 screening ( already document ) bone marrow aspirate/biopsy ( BMA ) determine subject eligibility trial . Subjects undergo leukapheresis within 14 day screen . Once successful manufacture WT1 TCR-transduced T cell confirm Sponsor , subject administer lymphodepletive conditioning regimen five day consist fludarabine x 5 day 30mg/m2 intravenous ( i.v . ) methylprednisolone x 1 day 500 mg i.v . Upon completion condition regimen , subject receive infusion WT1 TCR-transduced T cell ≤2 x 107/kg , follow daily IL-2 subcutaneous injection ( 1 x 106 units/m2 subcutaneous ( s.c. ) od ) 5 day . If IWG response report ( one criterion meet ) 3 month post-infusion , agree Investigator Sponsor , subject offer repeat infusion WT1 TCR-transduced T cell . Following infusion , subject enter intensive period out-patient follow-up observe acute complication toxicity . Subjects follow monthly clinic first 6 month routine safety clinical evaluation , include disease response evaluation . All subject followed-up minimum 12 month .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>Key Inclusion criterion : The trial recruit subject MDS AML receive hypomethylating agent therapy ( least 6 cycle azacitidine 4 cycle decitabine ) , EITHER : Relapsed , define fail maintain initial IWG response OR • Stable , define fail achieve IWG response Subjects receive hypomethylating agent therapy part combination regimen may eligible discussion Sponsor . 1 . Subjects age 18 year old diagnosis , EITHER : MDS IPSS intermediate 2 , high one follow FAB type : Refractory anaemia excess blast ( RAEB ) Chronic myelomonocytic leukaemia ( CMML ) least 10 % bone marrow blast ( WHO CMML II ) OR AML ( diagnose accord WHO classification 2008 revision ) 2 . Subjects document HLAA*0201 positive serotype 3 . Subjects less 30 per cent bone marrow blast 4 . Subjects relapse disease must less 5 per cent peripheral blast 5 . Subjects stable disease must less 10 per cent peripheral blast 6 . Subjects less double bone marrow blast count start hypomethylating agent therapy date screen 7 . Subjects complete screen 1 visit within minimum 28 day maximum 90 day since completion azacitidine decitabine therapy . Subjects exceed 90 day window may eligible discussion Sponsor . 8 . Subjects ECOG status 0 , 1 2 9 . Subjects least one cytopenia ( ANC &lt; 1000/μL , platelet count &lt; 75,000/μL , Hgb &lt; 11g/dL RBC transfusion dependence ) Key Exclusion criterion : improvement molecular response follow azacitidine treatment CMML patient white blood cell count &gt; 13 x 109/L Acute promyelocytic leukaemia ( FAB M3 Classification ) Uncontrolled intercurrent illness Active malignancy , except basal cell squamous cell skin cancer carcinoma situ cervix breast Known history Human Immunodeficiency Virus ( HIV ) , Hepatitis C virus ( HCV ) Hepatitis B virus ( HBV ) positive Human TLymphocyte Virus ( HTLV ) Syphilis . • Active autoimmune disease Clinically significant nonhematologic toxicity prior therapy chemotherapy high grade 1 per Common Terminology Criteria Adverse Events ( CTCAE ) ( v 4.0 ) Subjects require haemodialysis peritoneal dialysis Pregnant lactate woman Subjects unwilling unable use adequate contraceptive precaution screen throughout trial Subjects undergone major surgery without full recovery within last 28 day prior screen Subjects know hypersensitivity cyclophosphamide , fludarabine , methylprednisolone IL2 ( Interleukin2 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Gene Therapy</keyword>
	<keyword>WT1 TCR</keyword>
	<keyword>Gene modify T cels</keyword>
</DOC>